ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment by allowing people to start directly with injections.
Read the full press release here.
Source : ViiV Healthcare
Related HIV and Co-Infections News
-
Spotlight: South Africa’s ARV programme hardly grew in 2025, according to latest estimates
-
[Press release] ViiV Healthcare aims to close treatment gaps for children living with HIV with paediatric Dovato marketing applications to the EMA and FDA
-
Infectious Disease Advisor: Dolutegravir plus lamivudine maintains HIV-1 suppression without HBV reactivation
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.